References
- Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236–301
- Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10: S31–47
- Parfrey NA. Improved diagnosis and prognosis of mucormycosis: A clinicopathologic study of 33 cases. Medicine (Baltimore) 1986; 65: 113–23
- Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851–856
- Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med 1996; 35: 540–554
- Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol 1997; 99: 331–336
- Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230–240
- Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234
- Sun QN, Fothergill AQ, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581–1582
- Dannaoui E, Meletiadis J, Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45–52
- Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–1151
- Larone DH. Medically Important Fungi: A Guide to Identification4th Edition. ASM Press, Washington, D. C. 2002
- Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
- Ebright JR, Pace MT, Niazi AF. Septic thrombosis of the cavernous sinuses. Arch Intern Med 2001; 161: 2671–2676
- Talmi YP, Goldschmied-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg 2002; 127: 22–31
- Chakrabarti A, Das A, Sharma A, et al. Ten years’ experience in zygomycosis at a tertiary care centre in India. J Infect 2001; 42: 261–266
- Abzug MJ, Gardner S, Glode MP, et al. Heliport-associated nosocomial mucormycoses. Infect Control Hosp Epidemiol 1992; 13: 325–326
- Paydas S, Yavuz S, Disel U, et al. Mucormycosis of the tongue in a patient with acute lymphoblastic leukemia: a possible relation with use of a tongue depressor. Am J Med 2003; 114: 618–620
- Agger WA, Maki DG. Mucormycosis. A complication of critical care. Arch Intern Med 1978; 138: 925–927
- Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994; 39: 3–22
- Marty FM, Cosimi LA. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 951–952
- Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746